Red List

TRDAEntrada Therapeutics, Inc.

Healthcare · Biotechnology · micro-cap ($285M)
-53.8%
from rolling 252-day high of $16.45 set 2026-05-06 · 106d ago
Current
$7.60
Decline depth
-53.8%
Decline σ
1.9σ
TFC
2/5 bearish
Rolling 252-day high Up day Down day Last 90 trading days · data from Alpaca

Since it joined the list

$TRDA landed on the list 2026-06-04, down 57.4% from its 52-week high that day — now down -53.8%.

It has clawed back 3.4 percentage points off that level. It bottomed 64.6% below that high along the way.

Decline from the 52-week high as it stood on 2026-06-04 (fixed anchor) → today. Split-adjusted, Alpaca. Observed history, not a forecast.

Structural break signals

TRDA qualifies for the Red List on decline depth.

Decline depth
-53.8%
From rolling 252-day high of $16.45, 106d ago. Past the 40% Red List threshold.
Time-frame continuity
2/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3.
Decline sigma
1.9σ
Drop from local high over the last 20 bars, expressed in units of the stock's typical daily volatility (4.52% per day).

The structural read

What price action says about TRDA.

TRDA qualifies for the Red List on decline depth — down -53.8% from its rolling 252-day high. Past the 40% threshold, the deepest tier in the taxonomy. Depth plus recency: this is the pattern many investors call a falling knife.

Earnings on file: 2026-08-05. Tiering is unaffected by earnings dates — listings reflect price structure only.

Questions about TRDA

What people ask.

Why is TRDA on Broken Stocks?

TRDA qualifies for the Red List on decline depth. It is down -53.8% from its rolling 252-day high of $16.45, set on 2026-05-06 — 106d ago.

Is TRDA a falling knife?

By the most common technical definition — a steep, recent breakdown from a fresh high — yes. TRDA is down -53.8% from its 52-week high of $16.45, set 106d ago. That combination of depth (past the 30% Amber threshold) and recency (high set inside the last 120 days) is the textbook falling-knife pattern. Whether to try to catch it is a separate question — historically most attempts to bottom-pick continue lower before reversing. Broken Stocks flags the pattern; it does not recommend buying or selling.

Is TRDA a buy?

Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.

Where is TRDA trading inside its 52-week range?

At $7.60, TRDA sits 22.6% of the way from its 52-week low ($5.02) to its 52-week high ($16.45). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.

How fast has TRDA been declining?

The current 53.8% decline accrued over 106d, which annualizes to roughly -185.3% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.

How does TRDA compare to its sector?

There are 143 other Healthcare tickers on Broken Stocks: 69 Red, 35 Amber, 39 Watch, with 50 showing recovering structural signals. Median sector decline is -36.1% — TRDA's decline is deeper than the sector median.

Does TRDA's earnings date affect its tier?

No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-08-05) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.